Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

GlobeNewswireAug 15 07:45 ET

10-Q: Q2 2024 Earnings Report

SECAug 13 08:17 ET · Announcements

Express News | Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

ReutersAug 13 07:45 ET

Express News | Trading Halt: Halt Status Updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times

BenzingaAug 9 09:00 ET

Express News | Trading Halt: Halted at 7:50:00 P.m. ET - Trading Halt: Halt News Pending

BenzingaAug 8 19:50 ET

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds

Globe NewswireJun 28 09:15 ET